Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Diabetes Mellitus, Type 2 | 85 | 2024 | 760 | 12.790 |
Why?
|
Diabetes Mellitus | 90 | 2023 | 530 | 11.470 |
Why?
|
Hypoglycemia | 20 | 2023 | 49 | 7.000 |
Why?
|
Hypoglycemic Agents | 38 | 2021 | 288 | 5.750 |
Why?
|
Medication Adherence | 25 | 2020 | 267 | 5.580 |
Why?
|
Blood Glucose Self-Monitoring | 16 | 2021 | 43 | 3.960 |
Why?
|
Middle Aged | 161 | 2021 | 8284 | 3.810 |
Why?
|
Blood Glucose | 41 | 2024 | 346 | 3.780 |
Why?
|
Humans | 229 | 2024 | 18430 | 3.770 |
Why?
|
Male | 177 | 2024 | 10440 | 3.760 |
Why?
|
Glycated Hemoglobin A | 36 | 2021 | 233 | 3.470 |
Why?
|
Aged | 132 | 2024 | 6417 | 3.450 |
Why?
|
Female | 181 | 2024 | 13136 | 3.420 |
Why?
|
California | 76 | 2020 | 2365 | 3.090 |
Why?
|
Health Literacy | 10 | 2021 | 40 | 3.070 |
Why?
|
Diabetes Mellitus, Type 1 | 16 | 2022 | 124 | 3.060 |
Why?
|
Physician-Patient Relations | 11 | 2020 | 197 | 3.010 |
Why?
|
Residence Characteristics | 9 | 2017 | 256 | 2.510 |
Why?
|
Adult | 102 | 2023 | 7910 | 2.380 |
Why?
|
Communication Barriers | 8 | 2017 | 32 | 2.300 |
Why?
|
Ethnic Groups | 24 | 2016 | 501 | 2.070 |
Why?
|
Aging | 12 | 2019 | 165 | 2.070 |
Why?
|
Socioeconomic Factors | 31 | 2017 | 673 | 1.950 |
Why?
|
Food Supply | 5 | 2018 | 36 | 1.920 |
Why?
|
Diabetes Complications | 17 | 2020 | 119 | 1.890 |
Why?
|
Cardiovascular Diseases | 19 | 2021 | 630 | 1.860 |
Why?
|
Electronic Health Records | 10 | 2020 | 747 | 1.720 |
Why?
|
Cohort Studies | 40 | 2023 | 2672 | 1.640 |
Why?
|
Body Mass Index | 17 | 2017 | 974 | 1.640 |
Why?
|
Hospitalization | 9 | 2024 | 847 | 1.620 |
Why?
|
Managed Care Programs | 22 | 2017 | 347 | 1.580 |
Why?
|
Dyslipidemias | 3 | 2019 | 65 | 1.570 |
Why?
|
Insulin Resistance | 23 | 2016 | 129 | 1.560 |
Why?
|
Pharmaceutical Services | 6 | 2019 | 37 | 1.560 |
Why?
|
Insulin | 19 | 2021 | 208 | 1.510 |
Why?
|
Delivery of Health Care, Integrated | 11 | 2017 | 567 | 1.510 |
Why?
|
Risk Assessment | 18 | 2023 | 1143 | 1.480 |
Why?
|
Population Surveillance | 5 | 2018 | 271 | 1.470 |
Why?
|
Hispanic Americans | 20 | 2017 | 428 | 1.460 |
Why?
|
Risk Factors | 59 | 2023 | 3449 | 1.460 |
Why?
|
Dementia | 8 | 2023 | 105 | 1.260 |
Why?
|
Health Status Disparities | 5 | 2017 | 153 | 1.260 |
Why?
|
Insurance, Health | 9 | 2017 | 217 | 1.260 |
Why?
|
European Continental Ancestry Group | 20 | 2017 | 554 | 1.250 |
Why?
|
Depression | 13 | 2017 | 518 | 1.250 |
Why?
|
Postal Service | 7 | 2020 | 83 | 1.230 |
Why?
|
Aged, 80 and over | 30 | 2024 | 2003 | 1.220 |
Why?
|
Retrospective Studies | 23 | 2024 | 2550 | 1.220 |
Why?
|
United States | 48 | 2024 | 4164 | 1.190 |
Why?
|
Communication | 6 | 2020 | 202 | 1.170 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 4 | 2019 | 182 | 1.160 |
Why?
|
Culturally Competent Care | 2 | 2017 | 12 | 1.150 |
Why?
|
Patient Compliance | 9 | 2011 | 318 | 1.150 |
Why?
|
Health Expenditures | 3 | 2017 | 82 | 1.150 |
Why?
|
Continental Population Groups | 16 | 2016 | 315 | 1.110 |
Why?
|
Cross-Sectional Studies | 35 | 2017 | 1360 | 1.110 |
Why?
|
Commerce | 2 | 2017 | 49 | 1.090 |
Why?
|
Health Behavior | 13 | 2015 | 374 | 1.090 |
Why?
|
Quality of Life | 6 | 2017 | 529 | 1.050 |
Why?
|
Professional-Patient Relations | 5 | 2014 | 48 | 1.050 |
Why?
|
Glycemic Index | 5 | 2010 | 21 | 1.030 |
Why?
|
Follow-Up Studies | 25 | 2018 | 1269 | 1.030 |
Why?
|
Prescription Drugs | 3 | 2017 | 33 | 1.030 |
Why?
|
Language | 7 | 2016 | 52 | 1.020 |
Why?
|
Obesity | 14 | 2017 | 855 | 1.020 |
Why?
|
Diabetic Angiopathies | 11 | 2015 | 36 | 1.010 |
Why?
|
Electronic Prescribing | 3 | 2015 | 6 | 0.990 |
Why?
|
Coronary Disease | 2 | 2016 | 185 | 0.960 |
Why?
|
Atherosclerosis | 4 | 2021 | 51 | 0.950 |
Why?
|
Patient Acceptance of Health Care | 6 | 2018 | 407 | 0.950 |
Why?
|
Trust | 3 | 2014 | 31 | 0.940 |
Why?
|
Self Care | 9 | 2014 | 175 | 0.930 |
Why?
|
Registries | 20 | 2020 | 490 | 0.930 |
Why?
|
Emergency Service, Hospital | 5 | 2018 | 382 | 0.920 |
Why?
|
Drug Utilization | 5 | 2016 | 134 | 0.900 |
Why?
|
Glucose | 1 | 2023 | 30 | 0.900 |
Why?
|
Cost Sharing | 3 | 2017 | 40 | 0.890 |
Why?
|
Prospective Studies | 18 | 2020 | 1314 | 0.880 |
Why?
|
Tool Use Behavior | 1 | 2023 | 2 | 0.880 |
Why?
|
Arteriosclerosis | 11 | 2005 | 20 | 0.870 |
Why?
|
Cholesterol, LDL | 8 | 2016 | 125 | 0.830 |
Why?
|
Educational Status | 12 | 2014 | 205 | 0.830 |
Why?
|
Antidepressive Agents | 2 | 2014 | 162 | 0.820 |
Why?
|
Health Maintenance Organizations | 8 | 2010 | 479 | 0.820 |
Why?
|
African Americans | 13 | 2017 | 490 | 0.800 |
Why?
|
Treatment Outcome | 11 | 2021 | 1296 | 0.790 |
Why?
|
Biosensing Techniques | 1 | 2021 | 3 | 0.770 |
Why?
|
Deductibles and Coinsurance | 3 | 2017 | 31 | 0.760 |
Why?
|
Incidence | 20 | 2017 | 1314 | 0.760 |
Why?
|
Diabetic Neuropathies | 2 | 2016 | 13 | 0.750 |
Why?
|
Diabetic Nephropathies | 4 | 2015 | 28 | 0.740 |
Why?
|
Thiazolidinediones | 5 | 2010 | 54 | 0.730 |
Why?
|
Patient Education as Topic | 3 | 2020 | 214 | 0.730 |
Why?
|
Housing | 3 | 2017 | 40 | 0.720 |
Why?
|
Economic Recession | 2 | 2017 | 4 | 0.720 |
Why?
|
Data Accuracy | 2 | 2023 | 27 | 0.700 |
Why?
|
Crime | 3 | 2016 | 21 | 0.700 |
Why?
|
Health Records, Personal | 3 | 2015 | 13 | 0.700 |
Why?
|
Safety | 2 | 2016 | 45 | 0.690 |
Why?
|
Insurance, Pharmaceutical Services | 3 | 2014 | 27 | 0.660 |
Why?
|
Self Report | 6 | 2020 | 256 | 0.660 |
Why?
|
Insulin Detemir | 1 | 2018 | 1 | 0.640 |
Why?
|
Insulin, Isophane | 1 | 2018 | 2 | 0.640 |
Why?
|
Insulin Glargine | 1 | 2018 | 9 | 0.640 |
Why?
|
Stress, Psychological | 2 | 2016 | 147 | 0.620 |
Why?
|
Appointments and Schedules | 2 | 2011 | 34 | 0.620 |
Why?
|
Internet | 3 | 2017 | 243 | 0.600 |
Why?
|
Kidney Failure, Chronic | 6 | 2011 | 151 | 0.600 |
Why?
|
Environment | 2 | 2017 | 51 | 0.590 |
Why?
|
Emergency Medical Services | 1 | 2017 | 47 | 0.580 |
Why?
|
Patient Handoff | 1 | 2017 | 2 | 0.580 |
Why?
|
African Continental Ancestry Group | 9 | 2016 | 166 | 0.580 |
Why?
|
Health Status | 4 | 2017 | 328 | 0.570 |
Why?
|
Practice Patterns, Physicians' | 5 | 2017 | 350 | 0.560 |
Why?
|
Social Support | 3 | 2014 | 214 | 0.560 |
Why?
|
Cities | 1 | 2016 | 29 | 0.550 |
Why?
|
Cardiovascular Agents | 1 | 2016 | 25 | 0.550 |
Why?
|
Geographic Information Systems | 1 | 2016 | 16 | 0.540 |
Why?
|
Health Services Accessibility | 9 | 2017 | 320 | 0.540 |
Why?
|
Young Adult | 17 | 2020 | 2518 | 0.530 |
Why?
|
Primary Health Care | 5 | 2017 | 848 | 0.520 |
Why?
|
Smoking | 12 | 2021 | 494 | 0.520 |
Why?
|
Hypertriglyceridemia | 1 | 2015 | 13 | 0.520 |
Why?
|
Databases, Pharmaceutical | 1 | 2015 | 6 | 0.510 |
Why?
|
Time Factors | 12 | 2021 | 1136 | 0.510 |
Why?
|
Poverty Areas | 1 | 2015 | 22 | 0.500 |
Why?
|
Age Factors | 8 | 2017 | 965 | 0.500 |
Why?
|
Life Style | 3 | 2014 | 342 | 0.500 |
Why?
|
Renal Insufficiency, Chronic | 2 | 2015 | 180 | 0.490 |
Why?
|
Statistics as Topic | 1 | 2015 | 66 | 0.490 |
Why?
|
Coronary Artery Disease | 1 | 2015 | 133 | 0.480 |
Why?
|
Longitudinal Studies | 14 | 2020 | 724 | 0.480 |
Why?
|
Algorithms | 2 | 2015 | 241 | 0.470 |
Why?
|
Health Surveys | 10 | 2015 | 269 | 0.470 |
Why?
|
Fasting | 6 | 2016 | 48 | 0.460 |
Why?
|
Glucose Intolerance | 10 | 2013 | 45 | 0.460 |
Why?
|
Financing, Personal | 3 | 2017 | 24 | 0.460 |
Why?
|
Antihypertensive Agents | 7 | 2015 | 172 | 0.450 |
Why?
|
Glomerular Filtration Rate | 2 | 2015 | 157 | 0.450 |
Why?
|
Decision Making | 2 | 2014 | 204 | 0.450 |
Why?
|
Patient Access to Records | 1 | 2013 | 18 | 0.440 |
Why?
|
Outcome Assessment (Health Care) | 6 | 2012 | 254 | 0.440 |
Why?
|
Amputation | 2 | 2011 | 11 | 0.430 |
Why?
|
Cognition | 4 | 2022 | 82 | 0.420 |
Why?
|
Comorbidity | 15 | 2018 | 619 | 0.410 |
Why?
|
Temperature | 2 | 2017 | 18 | 0.390 |
Why?
|
Heart Failure | 4 | 2015 | 398 | 0.390 |
Why?
|
Clinical Laboratory Techniques | 1 | 2011 | 11 | 0.380 |
Why?
|
Adolescent | 13 | 2017 | 3798 | 0.380 |
Why?
|
Triglycerides | 2 | 2011 | 87 | 0.380 |
Why?
|
Multivariate Analysis | 9 | 2015 | 598 | 0.370 |
Why?
|
Proportional Hazards Models | 9 | 2017 | 743 | 0.370 |
Why?
|
Outcome and Process Assessment (Health Care) | 6 | 2010 | 110 | 0.370 |
Why?
|
Body Constitution | 5 | 2005 | 39 | 0.370 |
Why?
|
Myocardial Ischemia | 3 | 2004 | 24 | 0.360 |
Why?
|
Dental Care for Chronically Ill | 1 | 2010 | 1 | 0.360 |
Why?
|
Insurance, Dental | 1 | 2010 | 12 | 0.360 |
Why?
|
Healthcare Disparities | 5 | 2016 | 211 | 0.360 |
Why?
|
Chronic Disease | 3 | 2009 | 468 | 0.340 |
Why?
|
Anemia | 1 | 2010 | 32 | 0.340 |
Why?
|
Referral and Consultation | 1 | 2011 | 180 | 0.340 |
Why?
|
Office Visits | 1 | 2010 | 86 | 0.340 |
Why?
|
Medicare | 3 | 2015 | 214 | 0.330 |
Why?
|
Genetic Variation | 2 | 2015 | 87 | 0.330 |
Why?
|
Patient-Centered Care | 1 | 2011 | 228 | 0.330 |
Why?
|
Asian Americans | 6 | 2012 | 182 | 0.320 |
Why?
|
Quality of Health Care | 9 | 2011 | 347 | 0.320 |
Why?
|
Health Care Surveys | 8 | 2013 | 247 | 0.320 |
Why?
|
Hypolipidemic Agents | 5 | 2015 | 44 | 0.320 |
Why?
|
Myocardial Infarction | 4 | 2015 | 249 | 0.310 |
Why?
|
Electronic Mail | 2 | 2019 | 53 | 0.300 |
Why?
|
Alcohol Drinking | 5 | 2008 | 375 | 0.300 |
Why?
|
Physicians | 2 | 2020 | 141 | 0.290 |
Why?
|
Pregnancy Outcome | 2 | 2014 | 159 | 0.290 |
Why?
|
Premature Birth | 2 | 2020 | 138 | 0.290 |
Why?
|
Cost of Illness | 2 | 2007 | 100 | 0.280 |
Why?
|
Asian Continental Ancestry Group | 4 | 2016 | 90 | 0.270 |
Why?
|
Quality-Adjusted Life Years | 1 | 2006 | 41 | 0.270 |
Why?
|
Body Size | 1 | 2006 | 31 | 0.270 |
Why?
|
Carotid Artery Diseases | 2 | 2003 | 12 | 0.270 |
Why?
|
Risk | 4 | 2013 | 552 | 0.260 |
Why?
|
Health Personnel | 4 | 2020 | 126 | 0.250 |
Why?
|
Surveys and Questionnaires | 9 | 2018 | 1389 | 0.250 |
Why?
|
Prevalence | 9 | 2020 | 911 | 0.250 |
Why?
|
Confidence Intervals | 3 | 2021 | 253 | 0.250 |
Why?
|
Survival Rate | 7 | 2015 | 269 | 0.250 |
Why?
|
Poisson Distribution | 3 | 2015 | 94 | 0.250 |
Why?
|
Quality Improvement | 2 | 2017 | 207 | 0.250 |
Why?
|
Medicaid | 2 | 2017 | 211 | 0.240 |
Why?
|
Renal Dialysis | 2 | 2004 | 59 | 0.240 |
Why?
|
Linguistics | 2 | 2021 | 5 | 0.240 |
Why?
|
Cost-Benefit Analysis | 3 | 2015 | 270 | 0.240 |
Why?
|
Sex Factors | 7 | 2017 | 661 | 0.230 |
Why?
|
Insurance Coverage | 3 | 2017 | 136 | 0.230 |
Why?
|
Cognitive Dysfunction | 2 | 2022 | 47 | 0.230 |
Why?
|
Linear Models | 6 | 2013 | 243 | 0.230 |
Why?
|
Tuberculosis | 1 | 2004 | 20 | 0.230 |
Why?
|
Perception | 3 | 2016 | 59 | 0.230 |
Why?
|
Data Collection | 4 | 2014 | 275 | 0.230 |
Why?
|
Polypharmacy | 2 | 2016 | 13 | 0.230 |
Why?
|
Pharmacies | 2 | 2015 | 10 | 0.230 |
Why?
|
Oceanic Ancestry Group | 3 | 2012 | 33 | 0.220 |
Why?
|
Quality Indicators, Health Care | 4 | 2014 | 197 | 0.220 |
Why?
|
Epidemiology | 1 | 2003 | 5 | 0.220 |
Why?
|
Hypertension | 8 | 2015 | 524 | 0.220 |
Why?
|
Disease Management | 3 | 2015 | 143 | 0.220 |
Why?
|
Natural Language Processing | 2 | 2020 | 57 | 0.220 |
Why?
|
Health Knowledge, Attitudes, Practice | 4 | 2014 | 392 | 0.220 |
Why?
|
Prejudice | 3 | 2011 | 24 | 0.210 |
Why?
|
Glucose Tolerance Test | 7 | 2004 | 106 | 0.210 |
Why?
|
Patient Satisfaction | 4 | 2011 | 232 | 0.210 |
Why?
|
Life Tables | 1 | 2012 | 11 | 0.210 |
Why?
|
Hyperlipidemias | 4 | 2011 | 58 | 0.200 |
Why?
|
Abortion, Spontaneous | 1 | 2012 | 52 | 0.200 |
Why?
|
Preventive Health Services | 1 | 2003 | 166 | 0.200 |
Why?
|
Severity of Illness Index | 4 | 2019 | 476 | 0.200 |
Why?
|
Research Design | 5 | 2023 | 402 | 0.200 |
Why?
|
Numbers Needed To Treat | 1 | 2021 | 3 | 0.200 |
Why?
|
Anti-Bacterial Agents | 1 | 2003 | 142 | 0.200 |
Why?
|
Selection Bias | 1 | 2021 | 24 | 0.190 |
Why?
|
Diabetic Retinopathy | 2 | 2014 | 19 | 0.190 |
Why?
|
Motor Activity | 2 | 2013 | 215 | 0.190 |
Why?
|
Substance Abuse Treatment Centers | 1 | 2011 | 75 | 0.190 |
Why?
|
Health Services Research | 3 | 2013 | 264 | 0.190 |
Why?
|
Income | 5 | 2014 | 98 | 0.190 |
Why?
|
Cerebrovascular Disorders | 2 | 2013 | 35 | 0.190 |
Why?
|
Propensity Score | 1 | 2021 | 94 | 0.180 |
Why?
|
Pharmacy | 1 | 2020 | 12 | 0.180 |
Why?
|
Diabetic Ketoacidosis | 1 | 2020 | 4 | 0.180 |
Why?
|
Health Services Needs and Demand | 1 | 2021 | 109 | 0.180 |
Why?
|
Philippines | 3 | 2015 | 22 | 0.170 |
Why?
|
Cause of Death | 4 | 2015 | 185 | 0.170 |
Why?
|
Withholding Treatment | 1 | 2019 | 26 | 0.170 |
Why?
|
Genomic Imprinting | 1 | 1999 | 2 | 0.170 |
Why?
|
Sleep | 1 | 2020 | 57 | 0.170 |
Why?
|
Child Development | 1 | 2020 | 52 | 0.170 |
Why?
|
Poverty | 3 | 2015 | 182 | 0.170 |
Why?
|
Insurance Claim Review | 4 | 2015 | 70 | 0.160 |
Why?
|
Models, Statistical | 3 | 2017 | 185 | 0.160 |
Why?
|
Reindeer | 2 | 1996 | 2 | 0.160 |
Why?
|
Feeding Behavior | 2 | 2018 | 168 | 0.160 |
Why?
|
San Francisco | 2 | 2016 | 68 | 0.160 |
Why?
|
Caregivers | 1 | 2019 | 126 | 0.160 |
Why?
|
Genetic Predisposition to Disease | 2 | 2015 | 414 | 0.150 |
Why?
|
Dietary Fats | 2 | 2001 | 92 | 0.150 |
Why?
|
Logistic Models | 6 | 2014 | 962 | 0.150 |
Why?
|
Food | 2 | 2018 | 31 | 0.150 |
Why?
|
Albuminuria | 3 | 2015 | 41 | 0.150 |
Why?
|
Social Class | 2 | 2011 | 125 | 0.150 |
Why?
|
Population Dynamics | 1 | 2017 | 6 | 0.150 |
Why?
|
Reproducibility of Results | 6 | 2012 | 399 | 0.140 |
Why?
|
Forecasting | 2 | 2015 | 80 | 0.140 |
Why?
|
Health Benefit Plans, Employee | 1 | 2017 | 20 | 0.140 |
Why?
|
Vulnerable Populations | 1 | 2017 | 47 | 0.140 |
Why?
|
Medically Uninsured | 1 | 2017 | 61 | 0.140 |
Why?
|
Police | 1 | 2016 | 1 | 0.140 |
Why?
|
Longevity | 3 | 2022 | 13 | 0.140 |
Why?
|
Combined Modality Therapy | 1 | 2017 | 150 | 0.140 |
Why?
|
Pregnancy Complications, Infectious | 2 | 2020 | 142 | 0.140 |
Why?
|
Substance-Related Disorders | 1 | 2011 | 439 | 0.140 |
Why?
|
Needs Assessment | 1 | 2017 | 69 | 0.140 |
Why?
|
Influenza Vaccines | 1 | 2020 | 290 | 0.140 |
Why?
|
Influenza, Human | 1 | 2020 | 282 | 0.140 |
Why?
|
Self Efficacy | 2 | 2014 | 71 | 0.140 |
Why?
|
Appetite | 1 | 1996 | 1 | 0.140 |
Why?
|
Intestinal Diseases, Parasitic | 1 | 1996 | 1 | 0.140 |
Why?
|
Nematode Infections | 1 | 1996 | 1 | 0.140 |
Why?
|
Pregnancy | 4 | 2020 | 1516 | 0.130 |
Why?
|
Disease Progression | 4 | 2016 | 271 | 0.130 |
Why?
|
Analysis of Variance | 2 | 2015 | 167 | 0.130 |
Why?
|
Medical Order Entry Systems | 1 | 2015 | 15 | 0.130 |
Why?
|
Fast Foods | 1 | 2015 | 12 | 0.130 |
Why?
|
Nutrition Surveys | 2 | 2018 | 63 | 0.130 |
Why?
|
Cholesterol, HDL | 1 | 2015 | 80 | 0.130 |
Why?
|
Mutation Rate | 1 | 2015 | 3 | 0.130 |
Why?
|
Oligonucleotide Array Sequence Analysis | 1 | 2015 | 24 | 0.130 |
Why?
|
Exome | 1 | 2015 | 25 | 0.130 |
Why?
|
Blood Chemical Analysis | 1 | 2014 | 5 | 0.120 |
Why?
|
Spatial Analysis | 1 | 2014 | 12 | 0.120 |
Why?
|
Randomized Controlled Trials as Topic | 2 | 2007 | 342 | 0.120 |
Why?
|
Observational Studies as Topic | 1 | 2015 | 49 | 0.120 |
Why?
|
Safety-net Providers | 1 | 2015 | 63 | 0.120 |
Why?
|
Remission Induction | 1 | 2014 | 25 | 0.120 |
Why?
|
Drug Prescriptions | 2 | 2013 | 157 | 0.120 |
Why?
|
Health Resources | 1 | 2014 | 38 | 0.120 |
Why?
|
Weight Gain | 1 | 2016 | 181 | 0.120 |
Why?
|
Metabolic Syndrome | 2 | 2005 | 80 | 0.120 |
Why?
|
Regression Analysis | 4 | 2012 | 319 | 0.120 |
Why?
|
Metformin | 2 | 2020 | 61 | 0.110 |
Why?
|
Infectious Disease Transmission, Vertical | 1 | 2014 | 22 | 0.110 |
Why?
|
Case-Control Studies | 5 | 2013 | 1173 | 0.110 |
Why?
|
Health Care Costs | 2 | 2006 | 251 | 0.110 |
Why?
|
Terminology as Topic | 1 | 2013 | 21 | 0.110 |
Why?
|
Polymorphism, Single Nucleotide | 3 | 2016 | 412 | 0.110 |
Why?
|
Urinary Incontinence | 1 | 2013 | 33 | 0.110 |
Why?
|
Prediabetic State | 2 | 2013 | 53 | 0.110 |
Why?
|
Apolipoproteins | 1 | 2013 | 2 | 0.110 |
Why?
|
Lipoproteins | 1 | 2013 | 14 | 0.110 |
Why?
|
Reference Values | 3 | 2008 | 93 | 0.110 |
Why?
|
Antiviral Agents | 1 | 2014 | 95 | 0.110 |
Why?
|
Diptera | 1 | 1992 | 1 | 0.110 |
Why?
|
Humidity | 1 | 1992 | 2 | 0.110 |
Why?
|
Multicenter Studies as Topic | 3 | 2014 | 91 | 0.110 |
Why?
|
Psychometrics | 1 | 2013 | 124 | 0.100 |
Why?
|
Bariatric Surgery | 1 | 2014 | 130 | 0.100 |
Why?
|
Musculoskeletal Pain | 1 | 2012 | 28 | 0.100 |
Why?
|
Odds Ratio | 2 | 2013 | 701 | 0.100 |
Why?
|
Estrogen Replacement Therapy | 2 | 2003 | 104 | 0.100 |
Why?
|
Medical Records | 3 | 2007 | 106 | 0.100 |
Why?
|
Death Certificates | 1 | 2011 | 19 | 0.100 |
Why?
|
Discrimination (Psychology) | 1 | 2011 | 1 | 0.100 |
Why?
|
Interpersonal Relations | 1 | 2011 | 42 | 0.100 |
Why?
|
Sex Distribution | 4 | 2012 | 198 | 0.100 |
Why?
|
Prognosis | 5 | 2016 | 624 | 0.100 |
Why?
|
Ambulatory Care Information Systems | 1 | 2011 | 4 | 0.100 |
Why?
|
Age Distribution | 4 | 2012 | 261 | 0.090 |
Why?
|
Databases, Factual | 3 | 2013 | 327 | 0.090 |
Why?
|
Prescription Fees | 1 | 2010 | 4 | 0.090 |
Why?
|
Cost Control | 1 | 2010 | 25 | 0.090 |
Why?
|
Blood Pressure | 4 | 2016 | 310 | 0.090 |
Why?
|
Patients | 1 | 2010 | 38 | 0.090 |
Why?
|
Guideline Adherence | 2 | 2009 | 162 | 0.090 |
Why?
|
Comprehension | 1 | 2010 | 16 | 0.090 |
Why?
|
Hawaii | 2 | 2020 | 45 | 0.090 |
Why?
|
Accidental Falls | 1 | 2009 | 40 | 0.090 |
Why?
|
Insulin-Secreting Cells | 1 | 2009 | 19 | 0.090 |
Why?
|
Fractures, Bone | 1 | 2010 | 91 | 0.080 |
Why?
|
Primary Prevention | 1 | 2010 | 79 | 0.080 |
Why?
|
Drug Therapy | 1 | 2009 | 21 | 0.080 |
Why?
|
Patient Selection | 2 | 2008 | 198 | 0.080 |
Why?
|
Predictive Value of Tests | 5 | 2012 | 365 | 0.080 |
Why?
|
Body Weight | 2 | 2003 | 223 | 0.080 |
Why?
|
Exercise | 5 | 2016 | 495 | 0.080 |
Why?
|
Depressive Disorder, Major | 1 | 2009 | 127 | 0.080 |
Why?
|
International Classification of Diseases | 3 | 2015 | 87 | 0.080 |
Why?
|
Infant | 2 | 2020 | 1245 | 0.080 |
Why?
|
Social Problems | 1 | 2007 | 7 | 0.080 |
Why?
|
Treatment Refusal | 1 | 2008 | 38 | 0.080 |
Why?
|
Sulfonylurea Compounds | 1 | 2007 | 28 | 0.080 |
Why?
|
Torticollis | 1 | 2007 | 3 | 0.070 |
Why?
|
Drug Costs | 1 | 2007 | 40 | 0.070 |
Why?
|
Self Disclosure | 1 | 2007 | 24 | 0.070 |
Why?
|
Diagnostic Tests, Routine | 1 | 2007 | 22 | 0.070 |
Why?
|
Health Status Indicators | 1 | 2007 | 71 | 0.070 |
Why?
|
Walking | 1 | 2008 | 87 | 0.070 |
Why?
|
Angiotensin Receptor Antagonists | 2 | 2006 | 53 | 0.070 |
Why?
|
Angiotensin-Converting Enzyme Inhibitors | 2 | 2006 | 90 | 0.070 |
Why?
|
Translational Medical Research | 3 | 2012 | 39 | 0.070 |
Why?
|
Sex Characteristics | 3 | 2004 | 70 | 0.070 |
Why?
|
Seasons | 1 | 2017 | 105 | 0.070 |
Why?
|
Monte Carlo Method | 1 | 2006 | 17 | 0.070 |
Why?
|
Markov Chains | 1 | 2006 | 24 | 0.070 |
Why?
|
State Medicine | 1 | 2006 | 6 | 0.070 |
Why?
|
United Kingdom | 1 | 2006 | 32 | 0.070 |
Why?
|
Reagent Strips | 1 | 2006 | 1 | 0.070 |
Why?
|
Stroke | 2 | 2015 | 311 | 0.070 |
Why?
|
Education, Medical, Continuing | 1 | 2006 | 31 | 0.070 |
Why?
|
Mass Screening | 2 | 2014 | 690 | 0.070 |
Why?
|
PPAR gamma | 1 | 2005 | 10 | 0.060 |
Why?
|
Minority Groups | 2 | 2011 | 105 | 0.060 |
Why?
|
Age of Onset | 2 | 2020 | 82 | 0.060 |
Why?
|
Abdomen | 1 | 2005 | 21 | 0.060 |
Why?
|
Child | 2 | 2020 | 2571 | 0.060 |
Why?
|
Models, Genetic | 1 | 2005 | 24 | 0.060 |
Why?
|
Pedigree | 1 | 2005 | 58 | 0.060 |
Why?
|
Demography | 3 | 2013 | 108 | 0.060 |
Why?
|
Angiotensin II Type 1 Receptor Blockers | 1 | 2004 | 10 | 0.060 |
Why?
|
Self-Management | 1 | 2024 | 30 | 0.060 |
Why?
|
Hypercholesterolemia | 1 | 2004 | 33 | 0.060 |
Why?
|
Animals | 2 | 1996 | 261 | 0.060 |
Why?
|
Diagnostic Techniques, Ophthalmological | 1 | 2003 | 6 | 0.060 |
Why?
|
Lipoproteins, LDL | 1 | 2003 | 15 | 0.060 |
Why?
|
Genetics, Population | 1 | 2003 | 8 | 0.060 |
Why?
|
Progestins | 1 | 2003 | 28 | 0.050 |
Why?
|
Activities of Daily Living | 2 | 2013 | 96 | 0.050 |
Why?
|
Health Education | 1 | 2003 | 115 | 0.050 |
Why?
|
Comparative Effectiveness Research | 1 | 2023 | 77 | 0.050 |
Why?
|
Estrogens | 1 | 2003 | 73 | 0.050 |
Why?
|
Cluster Analysis | 2 | 2014 | 96 | 0.050 |
Why?
|
Survival Analysis | 2 | 2013 | 226 | 0.050 |
Why?
|
Databases, Bibliographic | 1 | 2012 | 6 | 0.050 |
Why?
|
Public Health | 1 | 2003 | 82 | 0.050 |
Why?
|
Fibrinogen | 1 | 2001 | 13 | 0.050 |
Why?
|
Ambulatory Care | 1 | 2004 | 266 | 0.050 |
Why?
|
Gestational Age | 1 | 2012 | 119 | 0.050 |
Why?
|
Alcoholics Anonymous | 1 | 2011 | 14 | 0.050 |
Why?
|
Texas | 2 | 2003 | 35 | 0.050 |
Why?
|
Adipose Tissue | 1 | 2001 | 60 | 0.050 |
Why?
|
C-Reactive Protein | 1 | 2001 | 58 | 0.050 |
Why?
|
Medical Records Systems, Computerized | 1 | 2001 | 95 | 0.050 |
Why?
|
Writing | 1 | 2020 | 12 | 0.050 |
Why?
|
Evidence-Based Medicine | 2 | 2014 | 195 | 0.050 |
Why?
|
Models, Theoretical | 2 | 2016 | 76 | 0.050 |
Why?
|
Heart Diseases | 1 | 2001 | 77 | 0.050 |
Why?
|
Colorado | 2 | 2003 | 211 | 0.050 |
Why?
|
Machine Learning | 1 | 2020 | 44 | 0.050 |
Why?
|
Attitude of Health Personnel | 2 | 2013 | 226 | 0.040 |
Why?
|
Executive Function | 1 | 2019 | 22 | 0.040 |
Why?
|
Delivery of Health Care | 2 | 2020 | 444 | 0.040 |
Why?
|
Proxy | 1 | 2019 | 4 | 0.040 |
Why?
|
Vaccines, Inactivated | 1 | 2020 | 70 | 0.040 |
Why?
|
Cognition Disorders | 1 | 2019 | 32 | 0.040 |
Why?
|
Nuclear Family | 1 | 1999 | 7 | 0.040 |
Why?
|
Child, Preschool | 1 | 2004 | 1478 | 0.040 |
Why?
|
Fathers | 1 | 1999 | 10 | 0.040 |
Why?
|
Confidentiality | 1 | 2019 | 30 | 0.040 |
Why?
|
Practice Guidelines as Topic | 1 | 2001 | 333 | 0.040 |
Why?
|
Focus Groups | 1 | 2019 | 154 | 0.040 |
Why?
|
Mothers | 1 | 1999 | 110 | 0.040 |
Why?
|
Geography | 1 | 2018 | 41 | 0.040 |
Why?
|
Qualitative Research | 1 | 2019 | 272 | 0.040 |
Why?
|
Costs and Cost Analysis | 1 | 2018 | 89 | 0.040 |
Why?
|
Biomarkers | 2 | 2013 | 308 | 0.040 |
Why?
|
Acitretin | 1 | 1997 | 1 | 0.040 |
Why?
|
Psoriasis | 1 | 1997 | 9 | 0.040 |
Why?
|
Software | 1 | 1997 | 21 | 0.040 |
Why?
|
Infant, Newborn | 1 | 2020 | 872 | 0.040 |
Why?
|
Professional Competence | 1 | 2016 | 12 | 0.040 |
Why?
|
Enhancer Elements, Genetic | 1 | 2016 | 1 | 0.030 |
Why?
|
Molecular Sequence Annotation | 1 | 2016 | 4 | 0.030 |
Why?
|
Computer Simulation | 1 | 1997 | 85 | 0.030 |
Why?
|
Introns | 1 | 2016 | 10 | 0.030 |
Why?
|
Islets of Langerhans | 1 | 2016 | 12 | 0.030 |
Why?
|
Gene Frequency | 1 | 2016 | 48 | 0.030 |
Why?
|
Transcription Factors | 1 | 2016 | 20 | 0.030 |
Why?
|
Quantitative Trait Loci | 1 | 2016 | 38 | 0.030 |
Why?
|
Unemployment | 1 | 2016 | 11 | 0.030 |
Why?
|
Abomasum | 1 | 1996 | 1 | 0.030 |
Why?
|
Antinematodal Agents | 1 | 1996 | 1 | 0.030 |
Why?
|
Cestoda | 1 | 1996 | 1 | 0.030 |
Why?
|
Coccidia | 1 | 1996 | 1 | 0.030 |
Why?
|
Ivermectin | 1 | 1996 | 1 | 0.030 |
Why?
|
Nematoda | 1 | 1996 | 1 | 0.030 |
Why?
|
Parasite Egg Count | 1 | 1996 | 1 | 0.030 |
Why?
|
Mortality | 1 | 1997 | 123 | 0.030 |
Why?
|
Animals, Domestic | 1 | 1996 | 4 | 0.030 |
Why?
|
Dose-Response Relationship, Drug | 2 | 2009 | 131 | 0.030 |
Why?
|
Diet | 3 | 2006 | 371 | 0.030 |
Why?
|
Urban Population | 1 | 2016 | 124 | 0.030 |
Why?
|
Morbidity | 1 | 2015 | 62 | 0.030 |
Why?
|
Information Storage and Retrieval | 1 | 2015 | 16 | 0.030 |
Why?
|
Epidemiological Monitoring | 1 | 2015 | 27 | 0.030 |
Why?
|
Feces | 1 | 1996 | 88 | 0.030 |
Why?
|
Glucose-6-Phosphatase | 1 | 2015 | 2 | 0.030 |
Why?
|
Vitamin A Deficiency | 1 | 1995 | 3 | 0.030 |
Why?
|
Glucagon-Like Peptide-1 Receptor | 1 | 2015 | 3 | 0.030 |
Why?
|
Genome-Wide Association Study | 1 | 2016 | 252 | 0.030 |
Why?
|
Genetic Association Studies | 1 | 2015 | 35 | 0.030 |
Why?
|
Models, Biological | 2 | 2006 | 32 | 0.030 |
Why?
|
Blood Pressure Determination | 1 | 2015 | 58 | 0.030 |
Why?
|
Mathematical Concepts | 1 | 2014 | 3 | 0.030 |
Why?
|
Genetic Loci | 1 | 2015 | 60 | 0.030 |
Why?
|
Self Administration | 1 | 2014 | 12 | 0.030 |
Why?
|
Acquired Immunodeficiency Syndrome | 1 | 1995 | 65 | 0.030 |
Why?
|
Maternal Age | 1 | 2014 | 80 | 0.030 |
Why?
|
Diabetic Foot | 1 | 2013 | 3 | 0.030 |
Why?
|
Indians, North American | 1 | 2013 | 50 | 0.030 |
Why?
|
Inflammation | 2 | 2005 | 63 | 0.030 |
Why?
|
Psychiatric Status Rating Scales | 1 | 2014 | 129 | 0.030 |
Why?
|
Kaplan-Meier Estimate | 1 | 2013 | 131 | 0.030 |
Why?
|
Chi-Square Distribution | 1 | 2013 | 160 | 0.030 |
Why?
|
Larva | 1 | 1992 | 1 | 0.030 |
Why?
|
Oviposition | 1 | 1992 | 1 | 0.030 |
Why?
|
Ovum | 1 | 1992 | 2 | 0.030 |
Why?
|
Sickness Impact Profile | 1 | 2012 | 28 | 0.030 |
Why?
|
Principal Component Analysis | 1 | 2012 | 23 | 0.030 |
Why?
|
Indiana | 1 | 2012 | 2 | 0.030 |
Why?
|
New Jersey | 1 | 2012 | 6 | 0.030 |
Why?
|
Employment | 1 | 2012 | 48 | 0.020 |
Why?
|
Kidney Diseases | 1 | 2011 | 55 | 0.020 |
Why?
|
Far East | 1 | 2011 | 6 | 0.020 |
Why?
|
Least-Squares Analysis | 1 | 2010 | 16 | 0.020 |
Why?
|
Mobility Limitation | 1 | 2010 | 16 | 0.020 |
Why?
|
HIV Infections | 1 | 1997 | 695 | 0.020 |
Why?
|
Choice Behavior | 1 | 2010 | 48 | 0.020 |
Why?
|
Diet, Diabetic | 1 | 2010 | 9 | 0.020 |
Why?
|
Pain | 1 | 2010 | 84 | 0.020 |
Why?
|
Energy Metabolism | 2 | 2001 | 50 | 0.020 |
Why?
|
Attitude to Health | 1 | 2011 | 177 | 0.020 |
Why?
|
Drug Administration Schedule | 1 | 2009 | 100 | 0.020 |
Why?
|
Bayes Theorem | 1 | 2009 | 69 | 0.020 |
Why?
|
Interviews as Topic | 1 | 2009 | 327 | 0.020 |
Why?
|
Medical Audit | 1 | 2008 | 41 | 0.020 |
Why?
|
Drug Utilization Review | 1 | 2007 | 26 | 0.020 |
Why?
|
Probability | 1 | 2008 | 86 | 0.020 |
Why?
|
Anxiety | 1 | 2009 | 156 | 0.020 |
Why?
|
Feedback | 1 | 2006 | 22 | 0.020 |
Why?
|
Information Systems | 1 | 2006 | 23 | 0.020 |
Why?
|
Reminder Systems | 1 | 2006 | 94 | 0.020 |
Why?
|
Linkage Disequilibrium | 1 | 2005 | 39 | 0.020 |
Why?
|
Chromosome Mapping | 1 | 2005 | 23 | 0.020 |
Why?
|
Haplotypes | 1 | 2005 | 43 | 0.020 |
Why?
|
Alleles | 1 | 2005 | 95 | 0.020 |
Why?
|
Genotype | 1 | 2005 | 253 | 0.020 |
Why?
|
Kidney Function Tests | 1 | 2003 | 22 | 0.010 |
Why?
|
Biology | 1 | 2003 | 1 | 0.010 |
Why?
|
Sociology | 1 | 2003 | 3 | 0.010 |
Why?
|
Genetic Diseases, Inborn | 1 | 2003 | 12 | 0.010 |
Why?
|
Ultrasonography | 1 | 2003 | 36 | 0.010 |
Why?
|
Anthropometry | 1 | 2003 | 67 | 0.010 |
Why?
|
Culture | 1 | 2003 | 29 | 0.010 |
Why?
|
Energy Intake | 1 | 2003 | 103 | 0.010 |
Why?
|
Genomics | 1 | 2003 | 66 | 0.010 |
Why?
|
Drug Therapy, Combination | 1 | 2003 | 119 | 0.010 |
Why?
|
Factor Analysis, Statistical | 1 | 2002 | 36 | 0.010 |
Why?
|
Creatinine | 1 | 2002 | 65 | 0.010 |
Why?
|
Carotid Arteries | 1 | 2001 | 10 | 0.010 |
Why?
|
Postmenopause | 1 | 2003 | 267 | 0.010 |
Why?
|
Infection | 1 | 2001 | 17 | 0.010 |
Why?
|
Body Composition | 1 | 2001 | 82 | 0.010 |
Why?
|
Leisure Activities | 1 | 2001 | 33 | 0.010 |
Why?
|
Pilot Projects | 1 | 1997 | 237 | 0.010 |
Why?
|
New York City | 1 | 1995 | 22 | 0.010 |
Why?
|
Vitamin A | 1 | 1995 | 15 | 0.010 |
Why?
|
Nutritional Status | 1 | 1995 | 30 | 0.010 |
Why?
|
Eating | 1 | 1995 | 38 | 0.010 |
Why?
|